Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARDS Aridis Pharmaceuticals	$0.00 +∞	$0.00	$0.00 ▼ $0.07	$5K	11.59	9,094 shs	6,460 shs
CLSN Imunon		$2.22	$1.80 ▼ $15.75	$13.91M	2.27	150,471 shs	711 shs
CVSI CV Sciences	$0.04 -11.0%	$0.03	$0.02 ▼ $0.06	$6.58M	0.6	228,439 shs	137,115 shs
DMAC DiaMedica Therapeutics	$4.01 +10.5%	$3.90	$3.19 ▼ $6.82	$171.95M	1.17	102,857 shs	323,707 shs
VCNX Vaccinex	$0.97 +3.2%	$0.82	$0.25 ▼ $8.90	$2.52M	1.1	56,017 shs	425 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARDS Aridis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-99.83%
CLSN Imunon	0.00%	0.00%	0.00%	0.00%	0.00%
CVSI CV Sciences	-11.00%	-9.64%	+20.68%	+19.46%	-26.80%
DMAC DiaMedica Therapeutics	+10.47%	+10.47%	+9.86%	+14.25%	+15.56%
VCNX Vaccinex	+3.19%	+21.25%	+18.29%	+11.49%	-85.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARDS Aridis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLSN Imunon	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CVSI CV Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	1.1992 of 5 stars	3.5	0.0	0.0	0.0	2.7	0.0	0.0
VCNX Vaccinex	0.8305 of 5 stars	0.0	5.0	0.0	0.0	0.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARDS Aridis Pharmaceuticals	0.00	N/A	N/A	N/A
CLSN Imunon	0.00	N/A	N/A	N/A
CVSI CV Sciences	0.00	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	3.00	Buy	$8.00	99.50% Upside
VCNX Vaccinex	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CLSN, ARDS, CVSI, DMAC, and VCNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/29/2025	DMAC DiaMedica Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARDS Aridis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
CLSN Imunon	$500K	0.00	N/A	N/A	$9.66 per share	0.00
CVSI CV Sciences	$15.70M	0.42	N/A	N/A	$0.01 per share	3.56
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
VCNX Vaccinex	$388K	6.50	N/A	N/A	($2.59) per share	-0.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARDS Aridis Pharmaceuticals	-$30.37M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CLSN Imunon	-$20.77M	N/A	0.00	N/A	N/A	-5,229.80%	-50.18%	-36.94%	N/A
CVSI CV Sciences	-$2.39M	N/A	0.00	∞	N/A	-12.25%	-89.43%	-22.75%	N/A
DMAC DiaMedica Therapeutics	-$24.44M	-$0.64	N/A	N/A	N/A	N/A	-61.35%	-55.53%	8/6/2025 (Estimated)
VCNX Vaccinex	-$20.25M	-$48.27	N/A	∞	N/A	N/A	N/A	-383.58%	8/12/2025 (Estimated)

Latest CLSN, ARDS, CVSI, DMAC, and VCNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	DMAC DiaMedica Therapeutics	-$0.18	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	DMAC DiaMedica Therapeutics	-$0.18	-$0.18	N/A	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARDS Aridis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CLSN Imunon	N/A	N/A	N/A	N/A	N/A
CVSI CV Sciences	N/A	N/A	N/A	N/A	N/A
DMAC DiaMedica Therapeutics	N/A	N/A	N/A	N/A	N/A
VCNX Vaccinex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARDS Aridis Pharmaceuticals	N/A	N/A	N/A
CLSN Imunon	0.13	6.52	6.52
CVSI CV Sciences	0.26	1.14	0.30
DMAC DiaMedica Therapeutics	N/A	8.02	8.02
VCNX Vaccinex	N/A	0.77	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARDS Aridis Pharmaceuticals	9.65%
CLSN Imunon	12.97%
CVSI CV Sciences	N/A
DMAC DiaMedica Therapeutics	10.12%
VCNX Vaccinex	50.11%

Insider Ownership

Company	Insider Ownership
ARDS Aridis Pharmaceuticals	5.50%
CLSN Imunon	4.66%
CVSI CV Sciences	1.30%
DMAC DiaMedica Therapeutics	7.30%
VCNX Vaccinex	51.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARDS Aridis Pharmaceuticals	30	53.32 million	50.39 million	Not Optionable
CLSN Imunon	27	7.10 million	6.77 million	Optionable
CVSI CV Sciences	70	184.79 million	182.39 million	Not Optionable
DMAC DiaMedica Therapeutics	20	42.88 million	39.75 million	Optionable
VCNX Vaccinex	40	2.60 million	1.26 million	No Data

CLSN, ARDS, CVSI, DMAC, and VCNX Headlines

Recent News About These Companies

Vaccinex presents promising cancer treatment data at ASCO

May 29, 2025 | uk.investing.com

Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025

May 29, 2025 | nasdaq.com

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

May 27, 2025 | globenewswire.com

AbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets

May 13, 2025 | finanznachrichten.de

AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets

May 13, 2025 | finance.yahoo.com

Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy

April 22, 2025 | markets.businessinsider.com

Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025

April 21, 2025 | quiverquant.comQ

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

April 21, 2025 | globenewswire.com

Vaccinex director resigns, no disagreement cited

March 21, 2025 | investing.com

Vaccinex plans Nasdaq exit as Alzheimer market pressure grows

March 10, 2025 | finance.yahoo.com

Vaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

March 8, 2025 | finanznachrichten.de

Vaccinex to delist common stock from Nasdaq

March 7, 2025 | markets.businessinsider.com

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

March 7, 2025 | globenewswire.com

Pepinemab by Vaccinex for Alzheimer’s Disease: Likelihood of Approval

December 30, 2024 | pharmaceutical-technology.comP

Vaccinex receives delisting notification from Nasdaq

December 17, 2024 | markets.businessinsider.com

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

December 17, 2024 | markets.businessinsider.com

Vaccinex Shares Tumble 63% On Nasdaq Delisting

December 17, 2024 | marketwatch.com

Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%

December 17, 2024 | finance.yahoo.com

Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock?

December 17, 2024 | benzinga.com

Vaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing Standards

December 17, 2024 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Why Amazon Could Be About To Breakout To $250
By Sam Quirke | June 19, 2025
View Why Amazon Could Be About To Breakout To $250

CLSN, ARDS, CVSI, DMAC, and VCNX Company Descriptions

Aridis Pharmaceuticals NASDAQ:ARDS

$0.0001 +0.00 (+∞)

As of 07/14/2025 02:38 PM Eastern

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

Imunon NASDAQ:CLSN

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

CV Sciences OTCMKTS:CVSI

$0.04 0.00 (-11.00%)

As of 07/14/2025 03:58 PM Eastern

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

DiaMedica Therapeutics NASDAQ:DMAC

$4.01 +0.38 (+10.47%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$4.02 +0.01 (+0.25%)

As of 07/14/2025 05:04 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Vaccinex NASDAQ:VCNX

$0.97 +0.03 (+3.19%)

As of 07/14/2025 03:49 PM Eastern

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time